| Date | Title | Description | Source |
| 04.04.2024 | Galapagos showcases innovative approach in hematological can... | Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies i... | einpresswi... |
| 04.04.2024 | Galapagos toont innovatieve aanpak in hematologische kankerz... | Twee presentaties en een postersessie met eerder gepresenteerde preliminaire data van fase 1/2 CD19 ... | einpresswi... |
| 22.02.2024 | Galapagos kondigt 2023 jaarresultaten en vooruitzichten 2024... | Financiële kerngetallen voor het hele jaar 2023: Netto groepsomzet van €783,5 miljoen in 2023, inclu... | einpresswi... |
| 22.02.2024 | Galapagos announces full year 2023 results and outlook for 2... | Full year 2023 key financials: Group net revenues of €783.5 million, including Jyseleca® net sales o... | einpresswi... |
| 15.02.2024 | Galapagos presents at EBMT-EHA annual meeting 2024 | Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational a... | einpresswi... |
| 15.02.2024 | Galapagos presenteert op de jaarlijkse EBMT-EHA meeting van ... | Toont betekenisvolle vooruitgang in gedecentraliseerde CAR T-cel productie en presenteert translatio... | einpresswi... |
| 31.01.2024 | Galapagos rondt transactie af om Jyseleca® business over te ... | Mechelen, België; 31 januari 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) heeft vanda... | einpresswi... |
| 31.01.2024 | Galapagos completes transaction to transfer Jyseleca® busine... | Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today anno... | einpresswi... |
| 07.12.2023 | Galapagos to Host KOL Event on December 10, 2023, at 11:00 A... | Mechelen, Belgium; 6 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today anno... | einpresswi... |
| 07.12.2023 | Galapagos organiseert een KOL-evenement op 10 december 2023 ... | Mechelen, België; 6 december 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) kondigde va... | einpresswi... |
| 15.06.2023 | Galapagos appoints Thad Huston as Chief Financial Officer an... | /EIN News/ -- Mechelen, Belgium; 15 June 2023, 22:01 CET; regulated information – Galapagos NV (Euro... | einpresswi... |
| 15.06.2023 | Galapagos benoemt Thad Huston tot Chief Financial Officer en... | /EIN News/ -- Mechelen, België; 15 juni 2023, 22:01 CET; gereglementeerde informatie - Galapagos NV ... | einpresswi... |
| 05.06.2023 | Galapagos toont CAR-T point-of-care productie en eerste fase... | Alle 7 van de 7 in aanmerking komende patiënten met recidief/refractaire chronische lymfatische leuk... | einpresswi... |
| 05.06.2023 | Galapagos to showcase CAR-T point-of-care manufacturing and ... | All 7 out of 7 eligible patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with... | einpresswi... |
| 05.05.2023 | Galapagos creëert nieuwe inschrijvingsrechtenplannen | /EIN News/ -- Mechelen, België; 5 mei 2023, 22:01 CET; gereglementeerde informatie – Galapagos NV (E... | einpresswi... |
| 05.05.2023 | Galapagos creates new subscription right plans | /EIN News/ -- Mechelen, Belgium; 5 May 2023, 22:01 CET; regulated information – Galapagos NV (Eurone... | einpresswi... |
| 04.05.2023 | Galapagos rapporteert financiële resultaten voor het eerste ... | Voortgang met immunologie en oncologie pijplijn: Eerste patiënten gedoseerd in pivotale fase 3 OLING... | einpresswi... |
| 04.05.2023 | Galapagos announces first quarter 2023 financial results | Progress with immunology and oncology pipeline: First patients dosed in pivotal Phase 3 OLINGUITO st... | einpresswi... |
| 27.02.2023 | Galapagos to present new data from long-term extension study... | Six presentations demonstrate Galapagos’ commitment to the inflammatory bowel disease (IBD) communit... | einpresswi... |
| 27.02.2023 | Galapagos presenteert nieuwe data van langetermijn-uitbreidi... | Zes presentaties tonen Galapagos' betrokkenheid bij inflammatoire darmziekten (IBD)
Nieuwe analyses ... | einpresswi... |
| 14.12.2021 | Ryvu announces option to license inflammation program exerci... | KRAKOW, Poland, Dec. 14, 2021 /PRNewswire/ -- Ryvu Therapeutics S.A. (WSE: RVU) announced today that... | marketscre... |
| 21.09.2021 | Galapagos : N.V., - Galapagos increases share capital throug... | Galapagos increases share capital through subscription right exercises
Mechelen, Belgium; 20 Septemb... | marketscre... |
| 17.09.2021 | Galapagos : N.V., - GALAPAGOS ANNOUNCES POSITIVE CHMP OPINIO... | GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WIT... | marketscre... |
| 15.07.2021 | Galapagos : N.V., - Galapagos reports positive topline resul... | Galapagos reports positive topline results with selective TYK2 inhibitor
GLPG3667 in Phase 1b psoria... | marketscre... |
| 15.07.2021 | Galapagos : N.V., - Galapagos demonstrates early clinical ac... | Galapagos demonstrates early clinical activity with
SIK2/3 inhibition in inflammation
Biologic effec... | marketscre... |
| 25.03.2021 | Galapagos : Statutory auditor's report on the non-consolidat... | Galapagos NV
Document subtitle= Verdana Heading 12 0/0 single
Galapagos NV
Statutory auditor's repor... | marketscre... |
| 07.08.2020 | GALAPAGOS NV
Galapagos : H1 Report 2020 | H1 Report
2020
CONTENTS
Contents The Galapagos group Letter from the management ....................... | marketscre... |
| 02.07.2019 | Gilead to seek FDA approval for rheumatoid arthritis drug th... | Shares of Gilead were up 1.4 percent on the Nasdaq Tuesday morning following the news. Shares of Gal... | medcitynew... |
| 31.03.2019 | Gilead, Galapagos’s filgotinib scores in Phase III rheumatoi... | Gilead’s shares rose 3 percent Friday morning following the news, while Galapagos’s shares were up 2... | medcitynew... |
| 13.09.2018 | Galapagos raises $300M on the back of first PhIII filgo... | → Galapagos $GLPG wasn’t about to let the success of its first Phase III for filgotinib — hand... | endpts.com... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appeti... | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. B... | endpts.com... |
| 13.05.2015 | Eurozone GDP, and Dupont shareholders vote — 5 things to kno... | Hello friends and Fortune readers.
Wall Street stock futures are higher this morning, helped by hope... | fortune.co... |
| 22.02.2012 | GSK grips arthritis compounds from drug partner Galapagos | The Galapagos/GSK strategic alliance dates to 2006, when the companies partnered to discover and dev... | medcitynew... |
| 21.09.2005 | Galapagos and BioFocus form a new force in drug discovery | Galapagos and BioFocus form a new force in drug discovery
21-09-2005
The boards of Galapagos NV, a g... | cambridgen... |
| - | Cambridge-based Qureight raises £1.5 million to curate colle... | Cambridge-based data company Qureight has raised £1.5 million seed funding to deliver the next gener... | tech.eu/20... |
| - | Gilead to seek FDA approval for rheumatoid arthritis drug th... | A U.S. biotech company plans to seek Food and Drug Administration approval for a drug to treat autoi... | medcitynew... |
| - | GSK grips arthritis compounds from drug partner Galapagos | GlaxoSmithKline (NYSE:GSK) is strengthening its prospects of developing a new arthritis treatment by... | medcitynew... |
| - | Gilead, Galapagos’s filgotinib scores in Phase III rheumatoi... | Biotech giant Gilead Sciences and a European partner scored a win Thursday with a positive Phase III... | medcitynew... |
